Navigation Links
Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Date:2/26/2009

BLISS-52 and BLISS-76, the ongoing Phase 3 trials of LymphoStat-B (belimumab), are the largest clinical trials ever conducted in lupus patients. HGS expects to report the first Phase 3 data for LymphoStat-B in July 2009 from the BLISS-52 trial, with results from BLISS-76 anticipated in November 2009. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

Darapladib: GSK Initiates Phase 3 Development Program

In December 2008, GSK initiated STABILITY, the first Phase 3 clinical trial to evaluate the efficacy and safety of treatment with the investigational Lp-PLA2 inhibitor darapladib to reduce the risk of cardiovascular events in men and women with chronic coronary heart disease. More than 15,000 patients will participate in STABILITY. Darapladib was discovered by GSK based on HGS technology. HGS will receive 10% royalties on worldwide sales if darapladib is commercialized, and has a 20% co-promotion option in North America and Europe.

Syncria(R): GSK Initiates Phase 3 Development; HGS to Receive $9 Million Milestone

In February 2009, GSK announced initiation of a Phase 3 clinical trial program to evaluate the efficacy, safety and tolerability of Syncria (albiglutide) in the long-term treatment of type 2 diabetes mellitus. Syncria is a novel long-acting form of GLP-1 (glucagon-like peptide 1) created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled to fees and milestone payments that could amount to as much as $183 million - including $24 million received to date and an additional $9 million milestone payment to be received in the first quarter of 2009. HGS is also entitled to single-digit royalties on worldwide sales if Syncria is commercialized.

CONFERENCE CALL

HGS management
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
2. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
3. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
4. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
5. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
6. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
7. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
10. 2008 Human Research Protection Award Recipients Announced
11. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Market Research Report on Global and Chinese ... and in-depth market survey on Global and ... firstly reviews the basic information of X-Ray Crystallography ... The report then explores global and China,s top ... specification, capacity, Production value, and market share etc. ...
(Date:8/29/2014)... ANGELES , Aug. 29, 2014  Chuma ... both financing alternatives and turnkey support services for ... announce that FINRA processed and approved the Company,s ... 29, 2014, CannaMed Corporation will be known as ... change was accomplished through a merger with the ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... Biosciences announced,today, the initiation of a Phase 2 ... management of acute infectious,mononucleosis. Currently, there are no ... or any other disease caused by,the Epstein-Barr virus ... of anti-viral activity,including inhibition of viral replication of ...
... Dec. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) ... ), has begun a Phase 1 clinical trial of ... R343,for the treatment of allergic asthma. R343 is the ... terms of the companies, 2005 collaboration agreement, Rigel,will receive ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... sleep knowing that, at any moment, her fever might ... order to keep me well aware of how she ... developed the TEMP ALARM to continuously monitor a child's ... develops a fever. This ensures that prompt medical care ...
(Date:8/30/2014)... August 30, 2014 Serving contented clients ... India, Profit By Outsourcing is now offering discount ... The company gives emphasize on putting forward the best ... to clients. Their dedicated team of professionals and web ... They can handle even the critical issues of web ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's #1 ... Day discount on all SEO services. While working with ... related to internet marketing. Their dedicated team of professionals ... have a deep understanding for their specialization. This further ... since the inception, they have worked with over 5000 ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The ... mesh lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston ... sever four cases selected for one of the ... on August 18, 2014, U.S. District Judge Joseph ... Virginia disagrees with Boston Scientific’s contention that a ...
(Date:8/30/2014)... "I had a handicapped friend who could not ... inventor from Wetumpka, Ala. "In order to help her be ... I came up with a way for her to use ... for the patent-pending Deezers to allow crutches to be used ... crutches, walkers, or canes at the beach. The device reduces ...
Breaking Medicine News(10 mins):Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3
... As world health leaders work vigorously to consider ... Consumer Specialty Products Association says taking simple precautions can ... something everyone should take seriously," said Chris Cathcart, CSPA ... to keep themselves and their families healthy now and ...
... A West Australian research team has made the world-first ... Liar, that leads other molecules into the nucleus of ... prostate, breast and colon cancers as well as leukemia. ... Australian Institute for Medical Research (WAIMR) led by Associate ...
... Ashley Koff R.D. helps Americans find healthier choices--BEVERLY HILLS, ... proud to announce Ashley Koff Approved (AKA), the unbiased ... several years of hearing her clients, medical colleagues, and ... recognized as a trusted source in the world of ...
... Spiderman Mulholland, one of the country,s leading forensic ... mold, is conducting investigations and working with environmental ... issues that have impacted homes and buildings in ... to date points to sulfur emissions that corrode ...
... reports show Google lobbied on the electronic medical ... contradicting the Internet giant,s earlier claims that Consumer ... false."Google,s report shows a total expenditure of $880,000 ... health-related initiatives; issues relating to online personal health ...
... system to reduce , workload, improve patient care, minimize ... Vocantas Inc., a developer of automated telephone outreach solutions, ... The Ottawa Hospital to manage patients in its Thrombosis ... in the Canadian Medical Association Journal shows that CallAssure ...
Cached Medicine News:Health News:Swine Influenza Outbreak - How to Stay Healthy 2Health News:WA discovery a key to blood cell development 2Health News:Introducing 'Ashley Koff Approved' (AKA): the Stamp of Nutrition for Optimal Health 2Health News:Forensic Expert Investigating Chinese Drywall Issue 2Health News:Consumer Watchdog: U.S. Senate Records Reveal Google Inc. Lobbying Campaign on Personal Medical Records Law Despite Internet Giant's Denials 2Health News:Consumer Watchdog: U.S. Senate Records Reveal Google Inc. Lobbying Campaign on Personal Medical Records Law Despite Internet Giant's Denials 3Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 2Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 3Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 4
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... Ergonomic Design for Unparalleled Comfort ... it. Notice the balance. Notice the trigger and ... left-handed. Thats because our pipettors are ergonomically designed ... long hours of pipetting. Productivity In The ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits all seven ... channel tip cone modules. ...
... , The new Finnpipette Novus is so user-friendly that ... few minutes. With the intuitive instantly familiar menu and ... functions you need quickly and easily. The large, clear ... names of all functions. The easily accessible two ...
Medicine Products: